Microplate assay for lipophilicity determination using intrinsic fluorescence of drugs: Application to a promising anticancer lead, pyridoclax.


Journal

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
ISSN: 1879-0720
Titre abrégé: Eur J Pharm Sci
Pays: Netherlands
ID NLM: 9317982

Informations de publication

Date de publication:
01 Apr 2019
Historique:
received: 07 12 2018
revised: 01 02 2019
accepted: 07 02 2019
pubmed: 12 2 2019
medline: 7 8 2019
entrez: 12 2 2019
Statut: ppublish

Résumé

Lipophilicity must be necessarily determined in drug discovery since this physicochemical property will directly influence the pharmacokinetics of a drug as its pharmacodynamics profile. Pyridoclax is an original lead, recently identified as very promising in treatment of chemoresistant cancers. The partition coefficient (Kp) of this anticancer drug was determined by microplate assays, well adapted in drug discovery, since being rapid, and requiring only poor drug amounts. The analytical approach was performed either by UV derivative spectrophotometry after validation thanks to a set of basic, neutral and acid reference substances, or originally, by raw fluorescence spectrophotometry by taking advantage of the pyridoclax intrinsic fluorescence. Large unilamellar vesicles (LUVs) were formulated from soybean-, egg-, or dipalmitoyl-phosphatidylcholine, characterized in terms of granulometric properties, ζ potential (determined by DLS), and of phospholipid content (quantified by

Identifiants

pubmed: 30742977
pii: S0928-0987(19)30063-6
doi: 10.1016/j.ejps.2019.02.010
pii:
doi:

Substances chimiques

Antineoplastic Agents 0
Liposomes 0
Membranes, Artificial 0
Phosphatidylcholines 0
Pyridines 0
pyridoclax 0
Water 059QF0KO0R
1-Octanol NV1779205D

Types de publication

Journal Article

Langues

eng

Pagination

75-83

Informations de copyright

Copyright © 2019 Elsevier B.V. All rights reserved.

Auteurs

Willy Smeralda (W)

Centre d'Etudes et de Recherche sur le Médicament de Normandie (CERMN), Normandie Univ, UNICAEN, F-14000 Caen, France.

Marc Since (M)

Centre d'Etudes et de Recherche sur le Médicament de Normandie (CERMN), Normandie Univ, UNICAEN, F-14000 Caen, France.

Sophie Corvaisier (S)

Centre d'Etudes et de Recherche sur le Médicament de Normandie (CERMN), Normandie Univ, UNICAEN, F-14000 Caen, France.

Rémi Legay (R)

Centre d'Etudes et de Recherche sur le Médicament de Normandie (CERMN), Normandie Univ, UNICAEN, F-14000 Caen, France.

Anne-Sophie Voisin-Chiret (AS)

Centre d'Etudes et de Recherche sur le Médicament de Normandie (CERMN), Normandie Univ, UNICAEN, F-14000 Caen, France.

Aurélie Malzert-Freon (A)

Centre d'Etudes et de Recherche sur le Médicament de Normandie (CERMN), Normandie Univ, UNICAEN, F-14000 Caen, France. Electronic address: aurelie.malzert-freon@unicaen.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs
Humans Male Female Health Knowledge, Attitudes, Practice Middle Aged
Animals Dietary Fiber Dextran Sulfate Mice Disease Models, Animal
Silicon Dioxide Water Hot Temperature Compressive Strength X-Ray Diffraction

Classifications MeSH